Document is current

Article History

Received: 29 June 2020

Accepted: 12 August 2020

First Online: 27 August 2020

Ethics approval and consent

: The study was approved by the Washington University in St. Louis Institutional Review Board, and all participants were consented for autopsy and sharing of samples.

: Not applicable.

: KH is an Eisai-sponsored visiting researcher at Washington University and has received salary from Eisai. RJB and Dr. David Holtzman (DH), the Department Chair of Neurology, has equity ownership interest in C2N Diagnostics and receive income from C2N Diagnostics for serving on the scientific advisory board. Washington University, with KH, NRB, CS, and RJB as co-inventors, receive royalty income based on technologies licensed by Washington University to C2N Diagnostics, including “Methods to Detect MTBR Tau Isoforms and Use Thereof” (KH, NRB, CS, RJB), “Methods to Detect Novel Tau Isoforms in CSF and Use Thereof” (KH, NRB, CS, RJB), "Tauopathy Biomarkers and Methods of Detection Thereof" (NRB, CS, RJB), and “Methods of Diagnosing and Treating Alzheimer's Disease Based on Rate of Phosphorylation of CSF Tau Sites"(NRB, RJB, Eric McDade). RJB has received honoraria from AC Immune, Janssen, and Roche as a speaker, from AC Immune, Amgen, Eisai, and Janssen as a consultant, and from Roche as an advisory board member.